HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHAs

This article was originally published in The Rose Sheet

Executive Summary

FDA's completed alpha hydroxy acid clinical trials are expected to be released in a final report by early September. The sunburn cell and minimal erythema dose studies demonstrated similar effects to those found in earlier studies conducted by the Cosmetic, Toiletry and Fragrance Association, which showed a slight but not troubling increase in skin's sensitivity to sunlight following application of 10% glycolic acid versus other vehicles. The agency's thymidine dimer results were not found to be statistically significant. FDA announced plans to begin the tests in late 1996 after CTFA's results led to the Cosmetic Ingredient Review's "safe as used" with qualifications ruling for the ingredient group
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS006977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel